William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating on June 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors surrounding Cardiff Oncology’s lead asset, onvansertib. The anticipation of additional Phase II trial results for onvansertib in treating RAS mutation-positive frontline metastatic colorectal cancer is a pivotal reason. The initial data from last December marked a significant turning point, validating the company’s strategic focus on this opportunity.
Hsieh was particularly impressed by the clear dose-response relationship, the drug’s tolerability when combined with Avastin and chemotherapy, and the correlation between dosage and tumor reduction speed, all of which suggest potential for long-term effectiveness. The expectation that onvansertib will maintain a response rate improvement of 20% over the standard-of-care further supports the Buy rating. This upcoming data release is anticipated to bolster the transition of onvansertib into a registrational program, enhancing its market potential.
In another report released on June 3, Piper Sandler also reiterated a Buy rating on the stock with a $10.00 price target.